Lantheus Pens Deal for Definity in China

Lantheus Medical Imaging said this week it brokered a deal to distribute its Definity contrast material for echocardiograms in China. Lantheus and Beijing Double-Crane Pharmaceutical Co., a leading drug company in Beijing, approved a 15-year agreement for exclusive distribution in China pending clinical trials, according to a company press release. Under the agreement, both companies will collaborate on designing and implementing the drug trials. Double-Crane also has the right of first negotiation to manufacture the injectable drug used to treat heart disease. Definity is currently approved in North America, Europe and a number of other countries.

Around the web

The patient, who was being cared for in the ICU, was not accompanied or monitored by nursing staff during his exam, despite being sedated.

The nuclear imaging isotope shortage of molybdenum-99 may be over now that the sidelined reactor is restarting. ASNC's president says PET and new SPECT technologies helped cardiac imaging labs better weather the storm.

CMS has more than doubled the CCTA payment rate from $175 to $357.13. The move, expected to have a significant impact on the utilization of cardiac CT, received immediate praise from imaging specialists.